On 11 March 2025, the Company applied to initiate corporate restructuring in accordance with the Swedish Corporate Restructuring Act (2022:964). On 13 March 2025, the District Court approved the application, a decision subsequently confirmed at a creditors’ meeting on 26 March 2025. The restructuring has since been extended twice, most recently by court approval on 19 September 2025, valid until 16 December 2025. The Swedish Tax Agency has appealed the court’s decision on the extension to the Svea Court of Appeal, which has granted leave to appeal. The Company will shortly submit a statement to the Svea Court of Appeal addressing the Tax Agency’s views.

The Reconstruction Plan has today been sent to the relevant parties, and the Company intends to request that the court schedule a plan negotiation shortly. The plan meeting, during which relevant parties will have the opportunity to vote on the Reconstruction Plan in accordance with Chapter 4, Section 15 of the Corporate Restructuring Act, will be held no earlier than three (3) and no later than five (5) weeks after the court’s decision to open the plan negotiation. The Company expects the plan meeting to take place around week 48, 2025. The exact date will be determined by the court. The confirmed date for the plan meeting, together with instructions for parties wishing to participate, will be announced by the Company via press release and on the Company’s website: www.peptonicmedical.se/investerare/foretagsrekonstruktion-2025/ as soon as possible.

Key Terms of the Proposed Rights Issue

The proposed rights issue comprises 93,374,091 units, each unit consisting of one hundred (100) shares and one hundred (100) warrants of series TO6. The subscription price per unit shall be SEK 0.16, corresponding to SEK 0.0016 per share, as the TO6 warrants are issued free of charge. Through the rights issue, the Company’s share capital will increase by a maximum of SEK 933,740.91 through the issuance of up to 9,337,409,100 shares, and by an additional SEK 933,740.91 through the issuance of up to 9,337,409,100 warrants of series TO6. Each TO6 warrant entitles the holder to subscribe for one (1) new share at a subscription price corresponding to 70 percent of the volume-weighted average price (VWAP) of the Company’s share on the trading venue during the period from 18 May 2026 up to and including 29 May 2026, however, not lower than the share’s quota value. Subscription of shares through exercise of the TO6 warrants may take place during the period from 1 June 2026 to 12 June 2026. The warrants will be subject to customary terms. The rights issue is conditional upon (i) the Reconstruction Plan becoming legally binding, (ii) reduction of share capital without cancellation of shares for allocation to unrestricted equity, whereby the nominal value per share is reduced from SEK 0.0046 to SEK 0.0001, and (iii) amendments to the articles of association.

The Reconstruction Plan, including the full terms of the share issues, share capital reduction, and amendments to the articles of association, is attached to this press release. The Reconstruction Plan and related documents are also available on the Company’s website: www.peptonicmedical.se/investerare/foretagsrekonstruktion-2025.

For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB                                           

Email: anna.linton@peptonicmedical.se                                                                                     

Phone: +46 70-244 92 07

About Peptonic Medical AB                                        

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

This disclosure contains information that PEPTONIC Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on October 23, 2025, 22:24 CET.